In our post-pandemic world following COVID-19 and its many vaccine development and supplies challenges, a renewed focus has been placed on the importance of temperature excursion management (TEM) in the modern clinical trial landscape. As a whole, the pharmaceutical industry is producing more expensive, valuable investigational products (IP) that require closer monitoring to ensure that clinical trial patients are only exposed to drugs or vaccines within known, safe stability conditions, and that product usage is optimized to mitigate waste.
The pandemic also expedited trends of decentralization, further emphasizing the need to collect accurate, cumulative temperature excursion data as supply chain models increasingly pivoted towards direct-to-patient models or other hybrid designs.
Though the bar for TEM standards has risen significantly industry-wide, there are still many challenges that sponsors and study teams face with the current systems in place, such as:
Has your study team faced any of these hurdles? Read on to learn how Signant’s TEM solution can resolve them to optimize your clinical supply chain management.
At Signant, we’ve made temperature excursion monitoring easier. Plus, our TEM solution can be integrated with any of our other clinical supply chain management solutions to optimize your trial from end to end.
Curious to hear more? Download our TEM brochure here or connect with us to speak with our in-house experts about your protocol.